Correlation Between Lyra Therapeutics and Durect

Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Durect at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Durect into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lyra Therapeutics and Durect, you can compare the effects of market volatilities on Lyra Therapeutics and Durect and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Durect. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Durect.

Diversification Opportunities for Lyra Therapeutics and Durect

0.81

Correlation Coefficient

Lyra Therapeutics  Durect

Very poor diversification

The 3 months correlation between Lyra and Durect is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Durect in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Durect and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Durect. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Durect has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Durect go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Durect

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Durect. In addition to that, Lyra Therapeutics is 1.11 times more volatile than Durect. It trades about -0.06 of its total potential returns per unit of risk. Durect is currently generating about -0.06 per unit of volatility. If you would invest  134.00  in Durect on September 28, 2024 and sell it today you would lose (37.00) from holding Durect or give up 27.61% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Lyra Therapeutics  vs.  Durect

Lyra Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Durect

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Durect has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Lyra Therapeutics and Durect

The main advantage of trading using opposite Lyra Therapeutics and Durect positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Durect can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Durect will offset losses from the drop in Durect's long position.

The idea behind Lyra Therapeutics and Durect pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.